Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | PRKCA | P17252 | 3/20 | 0.38 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28757144 | 0.97 | MEN1 (0.43) | CYP2C19MEN1KMT2ANAAAALDH1A1 | |
| SCHEMBL7421247 | 0.86 | NAAA (0.39) | CYP2C19MEN1KMT2ANAAAALDH1A1 | |
| SCHEMBL27602568 | 0.84 | MEN1 (0.44) | CYP2C19MEN1KMT2ANAAAALDH1A1 | |
| SCHEMBL13914170 | 0.83 | CYP4F2 (0.45) | MEN1KMT2ANAAAALDH1A1ATM | |
| SCHEMBL3707904 | 0.82 | CYP2C19 (0.53) | CYP2C19MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL2938022 | 0.81 | CYP2C19 (0.57) | CYP2C19MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL13945296 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2ANAAAALDH1A1TSHR | |
| SCHEMBL28186350 | 0.78 | NAAA (0.43) | MEN1KMT2ANAAAALDH1A1TSHR | |
| SCHEMBL12999536 | 0.77 | CYP2C19 (0.47) | CYP2C19MEN1KMT2ANAAAALDH1A1 | |
| SCHEMBL5032098 | 0.76 | ACHE (0.46) | CYP2C19MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2594557-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| EP-2594556-B1 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2016-08-10 | — | — | EP | disclosed |
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | COPPOLA GARY MARK (US) | 2014-10-02 | — | — | US | disclosed |
| US-8822534-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2014-09-02 | — | — | US | disclosed |
| EP-2435409-B1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| EP-2594556-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| EP-2594557-A1 | Substituted aminopropionic derivatives as neprilysin inhibitors | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | NOVARTIS AG (CH) | 2013-04-18 | — | — | US | disclosed |
| US-8394853-B2 | Substituted aminopropionic derivatives as neprilysin inhibitors | NOVARTIS AG (CH) | 2013-03-12 | — | — | US | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | CYP2C19 1196/4885MEN1 1133/4885KMT2A 3245/4885 |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CYP2C19 1226/4885MEN1 2146/4885KMT2A 2917/4885 |
| US-20140296240-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | CYP2C19 1196/4885MEN1 1133/4885KMT2A 3245/4885 |
| US-20130096127-A1 | SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS | MME, AGTR1, REN | CYP2C19 1196/4885MEN1 1133/4885KMT2A 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.